Suggestions
Shawn Titcomb
CEO of the Allele companies (Allele Capital, Allele Ventures, and Allele Communications) / Co-Founder and Executive Chairman of Majesty Therapeutics / Board Member of Praesidia Biotherapeutics
Shawn Titcomb is a seasoned professional in the life sciences and biotechnology industry with over 20 years of experience.14 He is the Co-Founder and Executive Chairman of Majesty Therapeutics, a biotechnology company focused on drug research and development.5
Professional Background
Shawn's career has been primarily focused on:
- Biotechnology
- Specialty pharmaceuticals
- New technologies in life sciences
He has demonstrated expertise in:
- Scientific and corporate due diligence
- Equity research
- Investments and investment banking
Current Roles
Shawn currently holds several significant positions:
- Founder & Executive Chairman at Majesty Therapeutics
- Founder & CEO of the Allele companies (Capital, Ventures, Communications)
- Board Member at Praesidia Therapeutics3
Previous Experience
Prior to his current roles, Shawn has held notable positions including:
- Head of Investment and Merchant Banking at Noble Life Science Partners
- Founding Partner at Variant Research Corporation
- Senior Vice President of Avalon Research Group1
Achievements
Throughout his career, Shawn has:
- Created and identified emerging life sciences companies with successful management teams
- Invested in and raised capital for life sciences companies, resulting in significant shareholder equity and valuations exceeding $1 billion
- Developed proprietary relationships with scientific key opinion leaders and life science executives1
Education and Qualifications
- Degree in Business Administration from the University of Denver
- Holds FINRA series 7, 63, and 79 licenses1
Shawn is known for being focused, competitive, smart, and energetic, with a great ability to understand both the narrative and financial aspects of businesses in the life sciences sector.2
Highlights
Congratulations to the team at our merchant portfolio company, Coya Therapeutics, Inc., on their collaboration with Dr. Reddy's Laboratories for the development and commercialization of COYA 302 for #ALS, as well as their concurrent $26.5M financing.
#tregs #ftd #alzheimersdisease #neurodegenerativediseases #collaboration #financing https://lnkd.in/eyBP9NRw
